➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Colorcon
Merck
Harvard Business School
Dow

Last Updated: August 5, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for ANX-510


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug ANX-510?

ANX-510 is an investigational drug.

There have been 10 clinical trials for ANX-510. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2006.

The most common disease conditions in clinical trials are Rectal Neoplasms, Lymphoma, Non-Hodgkin, and Delirium. The leading clinical trial sponsors are Mast Therapeutics, Inc., Thywill Latam Solutions SRL, and University of Sao Paulo.

Recent Clinical Trials for ANX-510
TitleSponsorPhase
Epigenetics in PostOperative Pediatric Emergence DeliriumUniversity of Sao PauloN/A
Safety and Efficacy of ANX-042 in Human Cardiorenal SyndromeNational Heart, Lung, and Blood Institute (NHLBI)Phase 1
Safety and Efficacy of ANX-042 in Human Cardiorenal SyndromeNational Institutes of Health (NIH)Phase 1

See all ANX-510 clinical trials

Clinical Trial Summary for ANX-510

Top disease conditions for ANX-510
Top clinical trial sponsors for ANX-510

See all ANX-510 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Merck
Baxter
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.